Showing results (341-350 of 397) with videos related to

Sort By:
Pageof 40
Journal of Thrombosis and Haemostasis : JTH|September 17, 2011
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopeniaB Psaila, J B Bussel, A L Frelinger, et al.
Lancet (London, England)|February 24, 2009
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trialJames B Bussel, Drew Provan, Tahir Shamsi, et al.
Molecular Genetics and Metabolism|July 2, 2010
Novel 47.5-kb deletion in RAB27A results in severe Griscelli Syndrome Type 2Lisa M Vincent, Fred Gilbert, Jennifer I DiPace, et al.
Therapeutic Advances in Hematology|October 23, 2023
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III studyDavid J Kuter, James B Bussel, Waleed Ghanima, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|January 18, 2020
Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopeniaMette Kjær, Christof Geisen, Çiğdem Akalın Akkök, et al.
British Journal of Haematology|February 26, 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacyDavid J Kuter, James B Bussel, Adrian Newland, et al.
Blood|August 20, 2020
Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter studyMarc Michel, Marco Ruggeri, Tomas Jose Gonzalez-Lopez, et al.
American Journal of Hematology|August 19, 2014
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopeniaWilliam Beau Mitchell, Mariana P Pinheiro, Nayla Boulad, et al.
Blood Advances|September 4, 2020
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopeniaTadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, et al.
The New England Journal of Medicine|November 30, 2007
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpuraJames B Bussel, Gregory Cheng, Mansoor N Saleh, et al.
Pageof 40